dapsone / Generic mfg. - LARVOL DELTA

Progressive IVIG-Induced Hepatitis Mimicking Metabolic Dysfunction-Associated Steatohepatitis: A Diagnostic Pitfall in the PostâCAR-T Setting (ACG 2026) - "Infectious/autoimmune work-up was negative and potential hepatotoxins (dapsone and levofloxacin) were stopped. Oncologic patients present unique diagnostic challenges, as concurrent chemotherapy, checkpoint inhibitors, and antimicrobials may be prematurely blamed for liver injury.[7] The AASLD guidance emphasizes that liver biopsy is especially useful when biochemistries fail to improve after drug dechallenge, and a given drug may produce more than one histopathological pattern.[3] Clinicians should maintain IVIG on the differential for progressive hepatitis, especially when conventional explanations fail to account for worsening injury despite appropriate interventions. Figure: A. 2025: Moderate fatty change and steatohepatitis (ballooning degeneration and few lymphocytes) B. 2026: Interface hepatitis with prominent portal inflammation (mostly lymphocytic with rare eosinophils) and mild interface changes; only mild fatty change Figure: C. 2026: Trichrome; areas of..."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Fibrosis • Genetic Disorders • Hematological Malignancies • Hepatology • Immunology • Inflammation • Liver Failure • Lymphoma • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Non-Hodgkin’s Lymphoma • Obesity

A Rare Case of Lichenoid Esophagitis in a Patient With Comorbid Leukocytoclastic Vasculitis and Antiphospholipid Syndrome (ACG 2026) - "Prior therapies including omeprazole, rabeprazole, oral budesonide, systemic prednisone, topical fluticasone, methotrexate, and dapsone were reported to be ineffective...Due to concerns for steroid-related complications, the patient was transitioned to oral tacrolimus 1 mg twice a day...While the predominant mechanisms of autoimmunity differ, this case suggests a possible association between LE and comorbid LCV and/or APS which warrants further investigation. Figure: Image 1: Esophageal stenosis of proximal esophagus 15 cm from the incisors found on baseline EGD in December, 2024 Figure: Image 2: Esophageal stenoses (narrowest 8 mm inner diameter by 1 cm length) found on EGD in September, 2025"

Clinical • Alopecia • Dermatomyositis • Dermatopathology • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lichen Planus • Metabolic Disorders • Myositis • Sjogren's Syndrome • Type 1 Diabetes Mellitus • Vasculitis

Dapsone-Induced Acute Pancreatitis: A Rare but Important Consideration in Drug-Induced Pancreatic Injury (ACG 2026) - "Medication review identified atorvastatin, pantoprazole, levothyroxine, and dapsone, with initiation 5 years prior for DH. This case adds to the growing body of reported cases, reinforcing ddx inclusion of drug-induced AP despite absence of causation-level evidence in patients on dapsone, although further studies are needed to evaluate pathogenesis and instigation regarding specific drug-related AP. Figure: Axial view of diffuse pancreatic edema and distended loops of bowel Figure: Coronal view of diffuse edema surrounding pancreas and hepatogastric structures"

Acute Kidney Injury • Barrett Esophagus • Celiac Disease • Dermatitis • Dyslipidemia • Endocrine Disorders • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hypertriglyceridemia • Immunology • Metabolic Disorders • Nephrology • Pancreatitis • Renal Disease

Antimicrobial resistance surveillance: a crucial pillar for sustainable leprosy control and chemoprophylaxis. (PubMed, Lancet Microbe) - "Although AMR in leprosy is less common than that in tuberculosis, resistance to rifampicin, dapsone, and fluoroquinolones highlights the need for systematic surveillance. We outline key challenges and propose pragmatic policy recommendations, including strengthening laboratory capacity, integrating surveillance into national programmes, and leveraging existing tuberculosis diagnostic networks. Embedding AMR surveillance within PEP strategies supports the long-term effectiveness of treatment and prevention efforts while minimising unintended consequences for global health."

Journal • Review • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and dexamethasone (IMW 2023) - P1 | "Both daratumumab (dara), an anti-CD38 antibody, and pomalidomide (pom), an immunomodulatory drug (IMiD), exhibit T-cell co-stimulatory effects and are clinically active when administered alone or with dexamethasone (dex) in pts with RRMM (Lonial et al. Cevostamab plus pom and dex shows promising activity in pts with RRMM and warrants further evaluation to optimize the benefit/risk profile. Biomarker and updated clinical data will be presented."

Clinical • Combination therapy • IO biomarker • P1 data • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology

Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities. (PubMed, Front Immunol) - "We report a 49-year-old woman with refractory anti-p200 pemphigoid who failed treatment with high-dose prednisone and dapsone and developed significant corticosteroid-related toxicity, including hypertension, hypertrichosis, steroid-induced myopathy, and psychological distress. Given her history of complicated diverticulitis requiring bowel resection, dupilumab was initiated as a steroid-sparing therapeutic option. Pruritus improved within two weeks, near-complete remission was achieved after two months, and sustained disease control was maintained for six months, allowing substantial corticosteroid tapering without treatment-related adverse events."

Journal • Real-world evidence • Cardiovascular • CNS Disorders • Dermatology • Gastrointestinal Disorder • Hypertension • Immunology • Myositis • Pruritus

Dapsone's Deception: masking hyperglycaemia via falsely low HbA1c (EADV 2026) - No abstract available

Diabetes

Successful treatment of Hidradenitis suppurativa and Dermatitis herpetiformis with dapsone and gluten-free diet – a case report (EADV 2026) - No abstract available

Case report • Clinical • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology

Recurrent eosinophilic cellulitis in a child successfully treated with dapsone (EADV 2026) - No abstract available

Clinical • Dermatology

Pyoderma gangrenosum lesions (EADV 2026) - "Rational treatment options could be escalation through 1st line therapies (topical steroids, tacrolimus, IL steroids, tetracyclines) to 2nd line therapies (prednisolone 0.5-1mg/kg/day, IV methylprednisolone, ciclosporin 4-5mg/kg/day, mycophenolate 1-3gm/day, methotrexate 15-25mg weekly, azathioprine 2-2.5mg/kg/day, dapsone, colchicine and then to 3rd line therapies (TNF inhibitors, IL-12/23 and IL-23 inhibitors, IL-17, IL-1, IL-36 and JAK inhibitors, IVIg, cyclophosphamide). C5a binding to its ligand complement component 5a receptor (C5aR) (also known as C5aR1) is not only a potent inducer of NETosis but is also a powerful chemoattractant, recruits and activates neutrophils. Avacopan (C5aR inhibitor), Vilobelimab (C5a neutralising antibody) as well as JAK inhibitors (NETosis pathway involves JAK-STAT signalling) would appear to be logical upstream inhibitors to prevent NETosis and PG and IL-36 inhibition for downstream inhibition of the cytokine storm in PG may well..."

Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pyoderma Gangrenosum • CTSG • ELANE • IL12A • IL17A • IL23A • MPO • PRSS3

Pustular dermatoses (EADV 2026) - "APF is a rare, chronic, relapsing disease of folds often associated with autoimmunity and treated variably with dapsone, cyclosporine, colchicine and, in recent reports, biologics such as spesolimab. Prof. Angelo Valerio Marzano Full Professor of Dermatology and Head Dermatology Unit , Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy Past Director of the Residency Program in Dermatology and Venereology Università degli Studi di Milano, Milan, Italy Voluntary Professor of Dermatology, Miller School of Medicine, University of Miami, Florida, USA"

Dermatology • Immunology • Psoriasis • Pustular Psoriasis • Rare Diseases

Recent recommendations for the treatment of lupus erythematosus (EADV 2026) - "For limited disease, topical corticosteroids and topical calcineurin inhibitors (tacrolimus, pimecrolimus) are standard; however, recent guidance increasingly favors calcineurin inhibitors or emerging topical Janus kinase (JAK) inhibitors for long-term maintenance to avoid corticosteroid-induced skin atrophy. For widespread, severe, or topically refractory CLE, systemic antimalarials—specifically hydroxychloroquine—remain the undisputed gold-standard first-line systemic intervention...When antimalarials fail, current algorithms prioritize the prompt introduction of second-line conventional immunosuppressants (methotrexate, mycophenolate mofetil, dapsone, or oral retinoids) to accelerate systemic glucocorticoid tapering. A key mandate in modern guidelines is the rapid reduction of prednisone to 5 mg/day or less within six months of initiation...The B-cell inhibitor belimumab and the type I interferon receptor antagonist anifrolumab are advised for patients with severe..."

Cutaneous Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Ophthalmology • Tobacco Cessation • IFNAR2 • TYK2

Autoimmune blistering diseases (EADV 2026) - "Updated evidence and recommendations concerning topical and systemic corticosteroids, azathioprine, dapsone, intravenous immunoglobulins and other immunomodulatory treatments will be discussed, together with current knowledge regarding biologic therapies and their use before, during and after pregnancy. To understand current evidence on the safety of immunosuppressive, immunomodulatory and biologic therapies during pregnancy. To improve counselling of pregnant patients with AIBDs, including delivery planning."

Immunology

LABD and epidermolysis bullosa acquisita (EADV 2026) - "The first module on LABD covers its bimodal epidemiology (affecting both children aged 4–5 years as Chronic Bullous Disease of Childhood, and adults aged 60–65 years), its IgA-mediated pathogenesis targeting BP180/LAD-1 and related basement membrane zone (BMZ) antigens, the classical "string of pearls" clinical sign in paediatric patients, and the critical role of drug-induced forms — with vancomycin as the leading culprit. Treatment algorithms are evidence-based, covering dapsone as the first-line agent for LABD and IgA-EBA, systemic corticosteroids combined with immunosuppressants for inflammatory EBA, and rituximab or IVIG for refractory disease. The lecture is anchored by two illustrative clinical cases Key Learning Objectives Recognize and distinguish the clinical phenotypes of LABD and EBA Apply the correct diagnostic algorithm, integrating direct immunofluorescence (DIF) with serration pattern analysis, indirect immunofluorescence on salt-split skin and..."

Bullous Pemphigoid • Crohn's disease • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Steven-Johnson Syndrome • LAD1

Histopathologi⁠cally Confirmed Nasal Rhinosporidiosis in an Adolescent Male Presenting with Long-Standing Right-Si⁠ded Nasal Obstruction and Epistaxis: A Case Report. (PubMed, Int Med Case Rep J) - "Postoperatively, oral dapsone 100 mg once daily was commenced for a planned six-month course after confirmation of normal glucose-6-phosphate dehydrogenase status...Nasal rhinosporidiosis should be considered in patients with long-standing unilateral nasal obstruction, recurrent epistaxis, and pond-water exposure. Complete surgical excision with cauterization and continued postoperative surveillance are important, particularly when histological margins are involved."

Journal • Infectious Disease

JAK Inhibitors in Colchicine Resistant FMF Patients: A Case-Based Review. (PubMed, Mediterr J Rheumatol) - "We conducted a retrospective case series of three adults with colchicine-resistant FMF who had previously demonstrated partial but inadequate responses to colchicine and dapsone combination therapy. JAK inhibitor therapy was associated with rapid, complete, and sustained remission in adults with colchicine-resistant FMF. These findings support the growing evidence that JAK inhibition may offer an effective oral alternative to biologics in refractory FMF."

Journal • Genetic Disorders • Hematological Disorders • Inflammation

Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion. (PubMed, J Eur Acad Dermatol Venereol) - "Optimal management of IGD relies on an aetiology-oriented approach. Withdrawal of causative drugs represents the most effective intervention when applicable. Topical and systemic corticosteroids remain first-line therapies; immunomodulatory and biologic agents are reserved for refractory disease."

Journal • Review • Cardiovascular • Dermatitis • Dermatology • Hematological Disorders • Immunology • Oncology • Rheumatology • Solid Tumor

SEVERE METHEMOGLOBINEMIA SECONDARY TO DAPSONE (CHEST 2026) - No abstract available

Hematological Disorders

THE DAMAGING EFFECTS OF DAPSONE, A HIDDEN CASE OF METHEMOGLOBINEMIA (CHEST 2026) - No abstract available

Clinical • Hematological Disorders

EOSINOPHILIC PNEUMONIA SANS EOSINOPHILS: AN ATYPICAL PRESENTATION OF DAPSONE-INDUCED LUNG INJURY (CHEST 2026) - No abstract available

Infectious Disease • Pneumonia • Respiratory Diseases

DAPSONE-INDUCED METHEMOGLOBINEMIA PRESENTING AS REFRACTORY HYPOXIC RESPIRATORY FAILURE IN ADVANCED HIV (CHEST 2026) - No abstract available

Metastases • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases

METHEMOGLOBINEMIA: A RARE COMPLICATION OF DAPSONE (CHEST 2026) - No abstract available

Hematological Disorders

Conformer-audited full-panel DFT refinement of frontier-orbital heterogeneity in classical sulfonamides: Beyond formal SO2NH identity. (PubMed, J Mol Graph Model) - "We examined thirteen classical sulfonamides and dapsone using a staged, quality-controlled workflow that separated exploratory GFN2-xTB/Composite-SEPI (the study-specific exploratory electronic-prioritization score) screening from full-panel B3LYP-D3BJ/def2-SVP optimization/frequency analysis, canonical PBE0-D4/def2-TZVP refinement with the conductor-like polarizable continuum model for water (CPCM(water)), and an orthogonal ωB97X-D4 sensitivity layer...In sulfadiazine, sulfamerazine, and sulfamethazine, the occupied and virtual frontier orbitals remained spatially separated between the aryl/aniline and diazine-containing regions. Diffuse-basis def2-TZVPD tests yielded negative vertical electron affinities and positive anion α-spin singly occupied molecular orbital (SOMO) energies for 14/14 molecules, making f+ and the dual descriptor basis-sensitive while f- remained comparatively robust. Formal SO2NH identity therefore masks reproducible electronic heterogeneity, but..."

Heterogeneity • Journal

Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges. (PubMed, Neuroprotection) - "In this review, we critically examine the therapeutic potential of selected antimicrobial classes, including tetracyclines (e.g., minocycline), macrolides (e.g., azithromycin), antimalarial agents (e.g., chloroquine/hydroxychloroquine), sulfones (e.g., dapsone), and antiparasitic agents (e.g., ivermectin), in non-infectious neurological diseases...Despite the encouraging evidence, we must carefully manage challenges such as antimicrobial resistance, off-target effects, and regulatory considerations. Further well-designed clinical trials are essential to validate their long-term safety and efficacy in neurodegenerative and neuroinflammatory diseases."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Epilepsy • Infectious Disease • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Vascular Neurology

Bullous eruption in the elderly - a case report with diagnostic challenges (PubMed, Praxis (Bern 1994)) - "The diagnosis was ultimately guided by the linear IgA deposition pattern along the dermoepidermal junction on direct immunofluorescence. This case highlights the diagnostic difficulties of this rare condition and the rapid clinical improvement following appropriate therapy."

Journal • Dermatology • Hematological Disorders • Immunology